Edesa Biotech Inc
EDSA1.480USD
+0.006+0.39%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
10.39MMarket Cap
LossP/E TTM
More Details of Edesa Biotech Inc Company
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Edesa Biotech Inc Info
Ticker SymbolEDSA
Company nameEdesa Biotech Inc
IPO dateAug 25, 2008
CEONijhawan (Pardeep)
Number of employees16
Security typeOrdinary Share
Fiscal year-endAug 25
Address100 Spy Crt
CityMARKHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeL3R 5H6
Phone19054751234
Websitehttps://www.edesabiotech.com/
Ticker SymbolEDSA
IPO dateAug 25, 2008
CEONijhawan (Pardeep)
Company Executives of Edesa Biotech Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Pardeep (Par) Nijhawan, M.D.
Dr. Pardeep (Par) Nijhawan, M.D.
Chief Executive Officer, Corporate Secretary, Director
Chief Executive Officer, Corporate Secretary, Director
1.24M
+0.71%
Mr. Patrick Marshall
Mr. Patrick Marshall
Independent Director
Independent Director
53.13K
+26.11%
Mr. Carlo Sistilli
Mr. Carlo Sistilli
Independent Chairman of the Board
Independent Chairman of the Board
30.94K
+182.86%
Mr. Sean Arthur Macdonald
Mr. Sean Arthur Macdonald
Independent Director
Independent Director
22.05K
+974.23%
Ms. Joan Chypyha
Ms. Joan Chypyha
Independent Director
Independent Director
11.03K
+37931.03%
Dr. Charles V. Olson
Dr. Charles V. Olson
Independent Director
Independent Director
11.00K
--
Dr. Michael J. Brooks, Ph.D.
Dr. Michael J. Brooks, Ph.D.
President
President
--
--
Mr. David Liu
Mr. David Liu
Independent Director
Independent Director
--
--
Mr. Peter J. Weiler
Mr. Peter J. Weiler
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Pardeep (Par) Nijhawan, M.D.
Dr. Pardeep (Par) Nijhawan, M.D.
Chief Executive Officer, Corporate Secretary, Director
Chief Executive Officer, Corporate Secretary, Director
1.24M
+0.71%
Mr. Patrick Marshall
Mr. Patrick Marshall
Independent Director
Independent Director
53.13K
+26.11%
Mr. Carlo Sistilli
Mr. Carlo Sistilli
Independent Chairman of the Board
Independent Chairman of the Board
30.94K
+182.86%
Mr. Sean Arthur Macdonald
Mr. Sean Arthur Macdonald
Independent Director
Independent Director
22.05K
+974.23%
Ms. Joan Chypyha
Ms. Joan Chypyha
Independent Director
Independent Director
11.03K
+37931.03%
Dr. Charles V. Olson
Dr. Charles V. Olson
Independent Director
Independent Director
11.00K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 17
Updated: Wed, Dec 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nijhawan (Pardeep)
9.46%
Rubric Capital Management LP
8.25%
Velan Capital Investment Management LP
8.25%
Stonepine Capital Management, LLC
8.25%
Nantahala Capital Management, LLC
7.50%
Other
58.30%
Shareholders
Shareholders
Proportion
Nijhawan (Pardeep)
9.46%
Rubric Capital Management LP
8.25%
Velan Capital Investment Management LP
8.25%
Stonepine Capital Management, LLC
8.25%
Nantahala Capital Management, LLC
7.50%
Other
58.30%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
17.04%
Hedge Fund
16.23%
Individual Investor
12.32%
Corporation
4.48%
Investment Advisor
1.22%
Research Firm
0.02%
Other
48.68%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
40
2.88M
32.19%
--
2025Q3
43
2.88M
32.32%
+768.59K
2025Q2
40
2.34M
45.62%
-714.36K
2025Q1
43
3.06M
26.82%
+1.17M
2024Q4
41
442.30K
18.67%
+46.16K
2024Q3
41
396.13K
19.53%
+10.63K
2024Q2
42
385.50K
23.02%
+42.84K
2024Q1
41
342.67K
25.48%
-465.55K
2023Q4
44
345.63K
25.10%
-182.33K
2023Q3
48
527.96K
26.28%
+5.81K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nijhawan (Pardeep)
1.22M
17.27%
+5.98K
+0.49%
Sep 11, 2025
Rubric Capital Management LP
687.50K
9.77%
--
--
Jun 30, 2025
Velan Capital Investment Management LP
687.50K
9.77%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
625.00K
8.88%
--
--
Jun 30, 2025
Pardeep Nijhawan Medicine Professional Corporation
341.70K
4.86%
-18.88K
-5.24%
Feb 12, 2025
Brooks (Michael J Ph.D.)
224.87K
3.2%
+207.20K
+1172.68%
May 29, 2025
Marshall (Patrick)
53.13K
0.76%
+11.00K
+26.11%
May 29, 2025
The Vanguard Group, Inc.
15.86K
0.23%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
27.96K
0.4%
-1.01K
-3.50%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 10, 2023
Merger
7→1
Oct 10, 2023
Merger
7→1
Oct 10, 2023
Merger
7→1
Oct 10, 2023
Merger
7→1
Date
Type
Ratio
Oct 10, 2023
Merger
7→1
Oct 10, 2023
Merger
7→1
Oct 10, 2023
Merger
7→1
Oct 10, 2023
Merger
7→1
FAQs
Who are the top five shareholders of Edesa Biotech Inc?
The top five shareholders of Edesa Biotech Inc are:
Nijhawan (Pardeep) holds 1.22M shares, accounting for 17.27% of the total shares.
Rubric Capital Management LP holds 687.50K shares, accounting for 9.77% of the total shares.
Velan Capital Investment Management LP holds 687.50K shares, accounting for 9.77% of the total shares.
Nantahala Capital Management, LLC holds 625.00K shares, accounting for 8.88% of the total shares.
Pardeep Nijhawan Medicine Professional Corporation holds 341.70K shares, accounting for 4.86% of the total shares.
Nijhawan (Pardeep) holds 1.22M shares, accounting for 17.27% of the total shares.
Rubric Capital Management LP holds 687.50K shares, accounting for 9.77% of the total shares.
Velan Capital Investment Management LP holds 687.50K shares, accounting for 9.77% of the total shares.
Nantahala Capital Management, LLC holds 625.00K shares, accounting for 8.88% of the total shares.
Pardeep Nijhawan Medicine Professional Corporation holds 341.70K shares, accounting for 4.86% of the total shares.
What are the top three shareholder types of Edesa Biotech Inc?
The top three shareholder types of Edesa Biotech Inc are:
Nijhawan (Pardeep)
Rubric Capital Management LP
Velan Capital Investment Management LP
Nijhawan (Pardeep)
Rubric Capital Management LP
Velan Capital Investment Management LP
How many institutions hold shares of Edesa Biotech Inc (EDSA)?
As of 2025Q4, 40 institutions hold shares of Edesa Biotech Inc, with a combined market value of approximately 2.88M, accounting for 32.19% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.14%.
What is the biggest source of revenue for Edesa Biotech Inc?
In --, the -- business generated the highest revenue for Edesa Biotech Inc, amounting to -- and accounting for --% of total revenue.
